menu
    • menu

    Company profile for Tempest Therapeutics

    NEW Drugs in Dev: 3
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest has assembled an experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by ...
    Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest has assembled an experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by a syndicate of leading US and China-based venture capital firms.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tempest TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7000 Shoreline Court Suite 275 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tempesttx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tempesttx
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Bio-Europe Spring

    Bio-Europe Spring

    Not Confirmed

    envelop Contact Supplier

    Bio-Europe Spring

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tempest Reveals 2025 Financials And Business Update
    Tempest Reveals 2025 Financials And Business Update

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264681/0/en/Tempest-Reports-Year-End-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Tempest Therapeutics Announces Up To $6 Million Private Placement
    Tempest Therapeutics Announces Up To $6 Million Private Placement

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260325/0/en/Tempest-Therapeutics-Announces-Up-To-6-Million-Private-Placement.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Tempest Partners on TPST-2003 Ahead of US Registrational Study
    Tempest Partners on TPST-2003 Ahead of US Registrational Study

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3253691/0/en/Tempest-Announces-Partnership-for-TPST-2003-in-Preparation-for-Planned-U-S-Registrational-Study-in-2026.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Tempest Announces REDEEM-1 Interim Results for TPST-2003
    Tempest Announces REDEEM-1 Interim Results for TPST-2003

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244522/0/en/Tempest-Announces-Interim-Results-from-Ongoing-REDEEM-1-Trial-of-TPST-2003-Preparing-for-Potential-U-S-Registrational-Study-in-2026.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Tempest Outlines Plans for Newly Acquired Dual-Targeting CAR-T
    Tempest Outlines Plans for Newly Acquired Dual-Targeting CAR-T

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236111/0/en/Tempest-Lays-Out-Strategic-Plan-to-Advance-Recently-Acquired-Dual-Targeting-CAR-T-Assets.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Tempest Finalizes Acquisition Of Dual-Targeting CAR-T Assets
    Tempest Finalizes Acquisition Of Dual-Targeting CAR-T Assets

    04 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/04/3232545/0/en/Tempest-Announces-Closing-of-Strategic-Acquisition-of-Dual-Targeting-CAR-T-Assets.html

    GLOBENEWSWIRE
    04 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search